A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...
A novel approach using native mass spectrometry has significantly advanced the understanding of stabilization mechanisms of ...
Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...
A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Nivolumab ...
The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding ...
Michael Castagna became CEO of MannKind and joined its board of directors in 2017, bringing 25+ years’ experience in ...
Sutro Biopharma, Inc.’s STRO share price has surged by 15.10%, which has investors questioning if this is right time to sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback